Publications by authors named "Mayra Valdes-Galvan"

Introduction: The use of filgrastim biosimilars for healthy adult and pediatric donor mobilization in hematopoietic stem cell transplantation has been met with increased safety and efficacy concerns in contrast to generic small molecule drugs. In Mexico, several filgrastim-intended copies (FIC) have been available and marketed since 2001, while no clinical comparability studies to evaluate their use in this setting have been published and thus are not considered to be true biosimilars. In this study, we report our experience using three different FIC products currently available (Filatil, Dextrifyl, and Biofilgran).

View Article and Find Full Text PDF

Introduction: Peripheral blood stem cell (PBSC) transplantation has become a routine procedure in pediatric oncology. A special group of PBSC donors are children weighing 20 kg or less. Limited vascular access and low blood volume puts them at a higher risk.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Mayra Valdes-Galvan"

  • Mayra Valdes-Galvan's research primarily focuses on the evaluation of hematopoietic stem cell mobilization techniques, particularly concerning the efficacy and safety of filgrastim biosimilars in both adult and pediatric donors in Mexico.
  • Her recent study published in 2019 assessed the effectiveness of three filgrastim-intended copies (Filatil, Dextrifyl, and Biofilgran) indicating a need for clinical comparability studies due to safety and efficacy concerns.
  • Additionally, her 2015 work highlighted innovative strategies for efficiently collecting peripheral blood stem cells in pediatric patients weighing 20 kg or less, addressing significant challenges in this vulnerable population.